The stocks that showed a little bit positive change on Thursday, are as follows: Sanofi, (NYSE:SNY), Hemispherx Biopharma, (HEB), MGM Resorts International, (NYSE:MGM), EQT Corporation, (NYSE:EQT)
Sanofi, (NYSE:SNY), with shares inclined 2.24%, closed at $51.05.
Hemispherx Biopharma, (HEB), with shares raised 1.72%, settled at $0.225.
MGM Resorts International, (NYSE:MGM), with shares enhanced 2.20%, and closed at $21.34.
EQT Corporation, (NYSE:EQT), increased 2.19%, and closed at $84.61.
Latest NEWS regarding these Stocks are depicted underneath:
Sanofi (NYSE:SNY)
Genzyme, a Sanofi (SNY), corporation, declared that the Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for Cerdelga® (INN: eliglustat), the only oral therapy for the treatment of adults with Gaucher disease type 1 in Japan. Cerdelga was approved by the U.S. Food and Drug Administration in August 2014, the European Commission in January 2015, and the Australian Therapeutics Goods Administration in February 2015.
The MHLW approval was based on data from the Cerdelga clinical development program, the largest clinical research program ever conducted in Gaucher disease type 1, with about 400 patients treated in 29 countries. The development program comprised of three Phase 3 clinical trials. In the Phase 3 treatment-naïve, placebo-controlled trial, ENGAGE, improvements were seen across the following endpoints after 9 months on Cerdelga: spleen size, platelet levels, hemoglobin levels, and liver volume. The second Phase 3 trial, ENCORE, was designed to assess disease stability in patients formerly treated with enzyme replacement therapy. That trial met the pre-specified criteria for non-inferiority to an enzyme replacement therapy (imiglucerase), which was a composite endpoint of the following parameters: spleen volume, hemoglobin levels, platelet counts, and liver volume.
The third Phase 3 trial, EDGE, comprised of 10 Japanese patients, and was designed to evaluate different dosing frequencies of Cerdelga (in patients formerly treated with enzyme replacement therapy or treatment naïve Gaucher disease patients). The EDGE trial comprised of an interim analysis of efficacy and safety in Japanese patients. Patients in all three Phase 3 studies continue to receive Cerdelga in the extension periods, and the majority of patients are in their 4th or 5th year of treatment.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
Hemispherx Biopharma, Inc. (HEB)
Formerly on March 24, Hemispherx Biopharma, Inc. (NYSEMKT:HEB), declared that the European partner, “Hemispherx Biopharma Europe N.V./S.A” gained a positive opinion from the COMP (Committee on Medical Products) regarding its Orphan Medicinal Product Application for Ampligen(R), an experimental therapeutic, to treat Ebola Virus Disease (EVD).
Orphan designation by the European Medicines Agency (EMA) is granted to promote the clinical development of drugs that target rare life-threatening conditions and which are predictable to provide noteworthy therapeutic advantage over any existing treatments and comprises some tropical diseases primarily found in developing nations as is the case for EVD. Hemispherx presented in vitro and in vivo data in appropriate preclinical models relevant to the EVD indication to the European Union (EU) Committee for Orphan Medicinal Products. In addition to the efficacy data, clinical safety information was also comprised of in the comprehensive application.
Hemispherx Biopharma, Inc., a specialty pharmaceutical corporation, is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States.
MGM Resorts International (NYSE:MGM)
MGM Resorts International (MGM), declared its partnership with Best Buddies Nevada to promote employment opportunities for persons with disabilities.
With the assist of a $120,000 MGM Resorts donation, spanning 2014 and 2015, Best Buddies Nevada will support a candidate selection process that will provide persons with intellectual and developmental disabilities (IDD) with opportunities for employment in jobs specified by MGM Resorts. For those candidates hired, Best Buddies Nevada will offer special on-the-job training and other workplace support in partnership with the corporation.
The mission of Best Buddies is to establish a global movement that creates opportunities for one-to-one friendships, integrated employment and leadership development for people with IDD. Through its Best Buddies Jobs program, the nonprofit matches skilled and qualified persons with IDD with businesses that are looking for enthusiastic and dedicated employees.
MGM Resorts International (MGM) is one of the world’s leading global hospitality companies, operating a portfolio of destination resort brands counting Bellagio, MGM Grand, Mandalay Bay and The Mirage. The Corporation is in the process of developing MGM National Harbor in Maryland and MGM Springfield in Massachusetts.
EQT Corporation (NYSE:EQT)
Formerly on March 11, EQT Corporation (EQT), an EQT Corporation, declared that its 2014 unitholder tax packages are accessible online. Investors can access their tax package and Plan K-1 at www.taxpackagesupport.com/eqm or by visiting the EQT Midstream Partners website at www.eqtmidstreampartners.com.
EQT Corporation, together with its auxiliaries, operates as a natural gas corporation in the United States. It operates in two segments, EQT Production and EQT Midstream. The EQT Production segment explores for, in addition to develops and produces natural gas, natural gas liquids (NGLs), and crude oil primarily in the Appalachian Basin. As of December 31, 2014, it had 10.7 trillion cubic feet of proved natural gas, NGLs, and crude oil reserves across about 3.4 million gross acres, counting about 630,000 gross acres in the Marcellus play.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
